Leukemia, B-Cell: all 190 studies
Page 1 of 2. Open to participants first (52), then studies with results posted, then the rest; newest registration first within each.
- A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLLNot yet recruitingNCT07899398Phase 2
- Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKINot yet recruitingNCT07819214Phase 2
- Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic MalignanciesNot yet recruitingNCT07710781Not applicable
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)RecruitingNCT07709000Phase 2
- Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing VenetoclaxRecruitingNCT07691047Not applicable
- A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL PatientsRecruitingNCT07671378Phase 2
- Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).Not yet recruitingNCT07624799Phase 2
- U96-CAR-T-Cells For R/R B-ALLNot yet recruitingNCT07511426Phase 1
- Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)RecruitingNCT07509151Phase 3
- CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLLRecruitingNCT07487428Not applicable
- A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received BlinatumomabRecruitingNCT07422337
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingNCT07342478Phase 3
- Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative NeoplasmsNot yet recruitingNCT07337967
- Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)Not yet recruitingNCT07166549Phase 1
- Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic LeukemiaNot yet recruitingNCT07113132
- A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLLNot yet recruitingNCT06979076Phase 1/2
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationRecruitingNCT06859424Phase 2
- CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and LymphomaRecruitingNCT06834529Phase 1/2
- Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID ProjectRecruitingNCT06821880
- Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With ZanubrutinibRecruitingNCT06812715Phase 2
- Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.RecruitingNCT06762431Phase 1/2
- A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell MalignanciesRecruitingNCT06708897Phase 1
- Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureRecruitingNCT06651970Phase 4
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingNCT06564038Phase 1/2
- A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.RecruitingNCT06542250Phase 1/2
- Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyRecruitingNCT06357754
- CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+RecruitingNCT06355739Not applicable
- CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHLRecruitingNCT06346912Early Phase 1
- Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)RecruitingNCT06345027Phase 1
- INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic LeukemiaNot yet recruitingNCT06209671Phase 1
- CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT06208735Phase 1
- A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell MalignanciesRecruitingNCT05932173Phase 1/2
- Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHLNot yet recruitingNCT05779930Early Phase 1
- Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United KingdomRecruitingNCT05557695
- Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell MalignanciesRecruitingNCT05487651Phase 1
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesRecruitingNCT05442515Phase 1/2
- Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic LeukemiaRecruitingNCT05350826Not applicable
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Phase 3
- Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)RecruitingNCT05099068Not applicable
- Caloric Restriction and Activity to Reduce Chemoresistance in B-ALLRecruitingNCT05082519Phase 2
- Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)RecruitingNCT05010564Phase 1
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)RecruitingNCT04728893Phase 2
- The OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesRecruitingNCT04329728Phase 1/2
- CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaRecruitingNCT04271410Phase 1/2
- Precision Exercise in Children With Malignant HemopathiesRecruitingNCT04090268Not applicable
- CAR-T Immunotherapy Targeting CD19- ALLNot yet recruitingNCT04016129Phase 1/2
- Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity ConditioningRecruitingNCT03852407Phase 2
- CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.RecruitingNCT03614858Phase 1/2
- A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and LeukemiaRecruitingNCT03383952Phase 1
- Chronic Lymphoid Leukaemia Observatory in Finistere Area, FranceRecruitingNCT03294980
- Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell StudiesEnrolling by invitationNCT02473757
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)RecruitingNCT00923507
- A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerTerminatedNCT04730349Phase 1/2Results posted
- CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)Active, not recruitingNCT03774654Phase 1Results posted
- Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic LeukemiaActive, not recruitingNCT03573700Phase 1/2Results posted
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesCompletedNCT03448393Phase 1Results posted
- BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or LeukaemiaCompletedNCT02933320Phase 1/2Results posted
- Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or LymphomaTerminatedNCT02518750Phase 2Results posted
- Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic LymphomaTerminatedNCT02227108Phase 2Results posted
- Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLCompletedNCT01659255Phase 1Results posted
- Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and LymphomaCompletedNCT01626495Phase 1/2Results posted
- A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic LeukemiaCompletedNCT01563055Phase 2Results posted
- Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01520922Phase 2Results posted
- PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT01500733Phase 2Results posted
- Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01292135Phase 1Results posted
- Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLLCompletedNCT01145209Phase 2Results posted
- Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After RituximabTerminatedNCT01119794Phase 2Results posted
- Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01109069Phase 2Results posted
- Safety of PCI-32765 in Chronic Lymphocytic LeukemiaCompletedNCT01105247Phase 1/2Results posted
- A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic LeukemiaCompletedNCT01077622Phase 2Results posted
- A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01063907Phase 1/2Results posted
- Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction TherapyTerminatedNCT01039376Phase 3Results posted
- Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic LeukemiaCompletedNCT00824265Phase 3Results posted
- Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)CompletedNCT00802737Phase 4Results posted
- Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00751296Phase 2Results posted
- Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic LeukemiaTerminatedNCT00748189Phase 3Results posted
- Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell MalignanciesTerminatedNCT00714259Phase 2/3Results posted
- Study of MLN8237 in Participants With Advanced Hematological MalignanciesCompletedNCT00697346Phase 1Results posted
- Stem Cell Transplantation for Patients With Cancers of the BloodCompletedNCT00467961Phase 2Results posted
- Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL PatientsCompletedNCT00410163Phase 2Results posted
- HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and AlemtuzumabCompletedNCT00349349Phase 2Results posted
- Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00230282Phase 2Results posted
- Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy VolunteersCompletedNCT06787131Phase 1
- Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsSuspendedNCT06662227Early Phase 1
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
- Retention Rate of Acalabrutinib in a Non-interventional SettingActive, not recruitingNCT05645172
- CAR-T Cells in the Treatment of Malignant Hematological TumorsStatus unknownNCT05619861Not applicable
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesActive, not recruitingNCT05589896Phase 1/2
- Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic MalignanciesWithdrawnNCT05570188Phase 1/2
- A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesActive, not recruitingNCT05362773Phase 1
- Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh NationalityCompletedNCT05095155
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
- Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLLCompletedNCT04883749Phase 2
- First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ MalignanciesStatus unknownNCT04763083Phase 1
- Induced-T Cell Like NK Cells for B Cell MalignanciesStatus unknownNCT04747093Phase 1/2
- Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)CompletedNCT04716075Phase 2
- Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic LeukemiaStatus unknownNCT04714593Phase 1/2
- CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04649983Phase 1/2
- Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04648475Phase 1/2
- Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Active, not recruitingNCT04608318Phase 3